Keywords: EMEA, CHMP opinions, AstraZeneca, Novartis, Octapharma, Roche, Aflunov, Brilique, Possia, Octagam, Avastin

Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma’s Octagam called for; Roche Avastin review

Article | 26 September 2010

Print This

Meeting highlights from the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) last week included good ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in